Search - tctmd.com

Displaying 1 - 20 of 96

Sort: Relevancy | Date

Andexanet Alfa Pulled From US Market

News Daily News

Andexanet Alfa Pulled From US Market

December 22, 2025

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

News Daily News

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

May 16, 2025

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

News Daily News

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

February 14, 2025

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

January 31, 2025

Scientific Statement Reviews Current Antithrombotic Options in PAD

News Daily News

Scientific Statement Reviews Current Antithrombotic Options in PAD

August 26, 2024

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

August 19, 2024

CMS Announces Negotiated Medicare Prices for First 10 Drugs

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

Lower-Dose Edoxaban May Be an Option After Age 80: ENGAGE AF-TIMI 48 Analysis

News Daily News

Lower-Dose Edoxaban May Be an Option After Age 80: ENGAGE AF-TIMI 48 Analysis

July 12, 2024

Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF

News Daily News

Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF

Michael O'Riordan

July 09, 2024

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

News Daily News

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

May 17, 2024

Diltiazem and DOAC Interaction Increases Bleeding Risk in AF

News Daily News

Diltiazem and DOAC Interaction Increases Bleeding Risk in AF

April 18, 2024

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

News Daily News

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

February 02, 2024

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

November 20, 2023

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

News Daily News

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

August 31, 2023

Andexanet Alfa, Reversal Agent for Factor Xa Inhibitors, Boosts Hemostasis

News Daily News

Andexanet Alfa, Reversal Agent for Factor Xa Inhibitors, Boosts Hemostasis

June 05, 2023

RECORD4 Trial of Rivaroxaban, Published in 2009, Still Turning Heads

News Daily News

RECORD4 Trial of Rivaroxaban, Published in 2009, Still Turning Heads

January 19, 2023

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

News Daily News

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

December 16, 2022

Don’t Skimp on Anticoagulation in Isolated Distal DVT: RIDTS

News Daily News

Don’t Skimp on Anticoagulation in Isolated Distal DVT: RIDTS

December 01, 2022

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

News Daily News

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

November 23, 2022

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.